Trial Profile
Risk factors of recurarization after insufficient sugammadex administration: Effects of obesity and obstructive sleep apnea
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Jun 2020
Price :
$35
*
At a glance
- Drugs Sugammadex (Primary)
- Indications Neuromuscular blockade
- Focus Therapeutic Use
- 08 Jun 2020 Planned End Date changed from 31 Mar 2021 to 31 Mar 2022.
- 06 Dec 2017 New trial record